Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05820841
Other study ID # ARCHED / GLA 2022-1
Secondary ID U1111-1284-70842
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 7, 2023
Est. completion date December 2028

Study information

Verified date August 2023
Source Universität des Saarlandes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be randomised to receive either R-miniCHOP alone or R-miniCHOP with Acalabrutinib.


Recruitment information / eligibility

Status Recruiting
Enrollment 330
Est. completion date December 2028
Est. primary completion date April 2028
Accepts healthy volunteers No
Gender All
Age group 61 Years and older
Eligibility Inclusion Criteria: Informed consent 1. Ability to understand the purpose and risks of the study and capable of giving signed informed consent which includes: 1. Compliance with the requirements and restrictions listed in the informed consent form (ICF). 2. Authorization to use protected health information/data [in accordance with the General Data Protection Regulation (GDPR)]. 2. Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses 3. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty. Age/Sex 4. Men and women >80 years of age or >60 up to 80 years of age and ineligible for full dose R-CHOP according to investigator assessment*. We recommend classifying patients aged 61-80 as full-dose R-CHOP ineligible if they fulfill one of the following criteria: ADL <5, IADL <6, CIRS-G =1 score = 3, or > 8 score = 2. 5. Male patients who are sexually active with women of childbearing potential (definitions see section 17.8) must agree to use highly effective forms of contraception with the addition of a barrier method (condom) during the study (see section 17.8.1) as well as to the restrictions mentioned in section 9.13. 6. Female patients of childbearing potential (definitions see 17.8) who are sexually active must agree to use highly effective forms of contraception while on the study as well as to the restrictions mentioned in section 9.13. Disease characteristics 7. Histologically proven, previously untreated CD20+ diffuse large B-cell lymphoma (DLBCL) according to the 2017 WHO classification including: 1. diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) 2. primary cutaneous DLBCL leg type 3. intravascular large B-cell lymphoma 4. EBV+ DLBCL, NOS 5. HHV8+DLBCL, NOS 6. primary mediastinal (thymic) large B-cell lymphoma 7. B-cell lymphoma, with intermediate features between DLBCL and classical Hodgkin lymphoma 8. follicular lymphoma grade 3B 9. high-grade B-cell lymphoma, NOS 10. high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements 11. T-cell/histiocyte-rich large B-cell lymphoma 12. DLBCL associated with chronic inflammation 13. ALK+ large B-cell lymphoma 14. large B-cell lymphoma with IRF4 rearrangement Please note: patients in whom indolent lymphoma is diagnosed concurrently with the one of the above listed diagnoses can also be included. 8. Disease Stage I with bulk =7.5cm, II, III or IV according to Ann Arbor Classification Type of patient and clinical characteristics 9. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. An ECOG Score of 3 is acceptable only if this is directly attributable to lymphoma. 10. Meet the following laboratory parameters: 1. Absolute neutrophil count (ANC) = 1500 cells/µl or platelet count = 100.000/µl unless directly attributable to lymphoma. 2. Serum AST and ALT =3 x upper limit of normal (ULN) unless directly attributable to lymphoma. 3. Total bilirubin =1.5 x ULN, unless directly attributable to Gilbert's syndrome or lymphoma. 4. Estimated creatinine clearance of =30 mL/min, calculated by Cockcroft-Gault (using actual body weight) (if male, [140-Age] x Mass [kg] / [72 x creatinine mg/dL]; multiply by 0.85 if female), or serum creatinine =2.5 x ULN. Exclusion Criteria: Medical conditions 1. Evidence of disease (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension and renal transplant) that, in the investigator's opinion, make it undesirable for the patient to participate in the study or that would jeopardize compliance with the protocol [e.g. a single score of 4 on one single category on the CIRS-G-Score (but not a cumulative score of 4)]. 2. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of randomization or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or LVEF < 40%. Patients with controlled, asymptomatic atrial fibrillation are allowed to enroll on study. 3. Severe pulmonary dysfunction (CTCAE grade 3 or 4) unless associated with lymphoma. 4. Severe psychiatric or neurologic disease that, in the investigator's opinion, make it undesirable for the patient to participate in the study or that would jeopardize compliance with the protocol. 5. Persistent neuropathy CTCAE grade 3 or 4. 6. Refractory nausea and vomiting, inability to swallow acalabrutinib, or malabsorption syndrome; chronic severe gastrointestinal disease, gastric restrictions, or bariatric surgery such as gastric bypass; partial or complete bowel obstruction, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment. 7. History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following: 1. Curatively treated localised basal cell carcinoma or localised squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ / low risk carcinoma of the prostate requiring only observation, as well as untreated low grade lymphoma except chronic lymphocytic leukemia. 2. Other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which patient is disease-free for =2 years (=5 years for those treated with chemotherapy) without further treatment or which are not expected to limit survival to < 2 years. 8. Received a live virus vaccination within 28 days of randomization. 9. Known history of infection with HIV. 10. Any active significant infection (e.g., bacterial, viral or fungal) as assessed by the investigator. 11. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML). 12. Serologic status reflecting active hepatitis B or C infection. 1. Patients who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative PCR result before randomization and must be willing to undergo DNA PCR testing during the study. Those who are HBsAg-positive or hepatitis B PCR positive will be excluded. 2. Patients who are hepatitis C antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded. 13. History of stroke or intracranial hemorrhage within 6 months before randomization. 14. History of clinically relevant bleeding diathesis (e.g., hemophilia, von Willebrand disease). 15. Major surgical procedure within 30 days before randomization. Note: If a patient had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug. 16. Breastfeeding or pregnant women. 17. Current life-threatening illness, medical condition, organ system dysfunction, social, geographical or economic condition which, in the Investigator's opinion, could compromise the patient's safety or put the study at risk. 18. Diagnosis of primary central nervous system lymphoma or secondary central nervous system or meningeal involvement by lymphoma 19. Diagnosis of Richter's Transformation/transformed CLL Prior/Concomitant therapy 20. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists. Patients using therapeutic low molecule weight heparin, direct oral anticoagulants or low dose aspirin will be eligible. Switching from vitamin K antagonists to one of the allowed anticoagulants above prior to trial entry is permitted. 21. Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor or inducer. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited. See details in section 9.12.1. 22. Prior exposure to a BTK inhibitor. 23. Prior anthracycline use =300 mg/m2. 24. Already initiated lymphoma therapy except for steroid (max. total dose of 1000mg), vincristine (max. 1 mg once) or rituximab (max. 375mg/m2) prephase. 25. Concurrent participation in another therapeutic clinical trial. 26. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrolment into this study. 27. Received any investigational drug within 30 days or 5 half-lives (whichever is shorter) before first dose of study drug.

Study Design


Intervention

Drug:
R-miniCHOP + Acalabrutinib
Rituximab i.v.: 375 mg/m2 (D0) Cyclophosphamide i.v.: 400 mg/m² (D1) Doxorubicin i.v.: 25 mg/m² (D1) Vincristine i.v.: 1 mg (D1) Prednisolone p.o.: 40 mg/m² (D1 to D5) Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8. Cycles repeated every 3 weeks
R-miniCHOP
Rituximab i.v.: 375 mg/m2 (D0) Cyclophosphamide i.v.: 400 mg/m² (D1) Doxorubicin i.v.: 25 mg/m² (D1) Vincristine i.v.: 1 mg (D1) Prednisolone p.o.: 40 mg/m² (D1 to D5). Cycles repeated every 3 weeks

Locations

Country Name City State
Germany MVZ am Klinikum Aschaffenburg Aschaffenburg
Germany Helios Klinikum Emil von Behring Berlin
Germany Onkologische Schwerpunktpraxis Kurfürstendamm Berlin
Germany Gemeinschaftspraxis Mohm/Prange-Krex Dresden
Germany Universitätsklinikum Gießen und Marburg, Standort Gießen Gießen
Germany Universitätsmedizin Greifswald Greifswald
Germany Universitätsmedizin Halle (Saale) Halle
Germany Saarland University Medical Center Homburg Saarland
Germany Städtisches Klinikum Karlsruhe Karlsruhe
Germany Johannes Wesling Klinikum Minden
Germany Rheinland Klinikum-Lukaskrankenhaus Neuss Neuss
Germany Brüderkrankenhaus St. Josef Paderborn
Germany CaritasKlinikum Saarbrücken St. Theresia Saarbrücken
Germany Klinikum Mutterhaus der Borromäerinnen Trier
Germany Krankenhaus der Barmherzigen Brüder Trier Trier
Germany Bundeswehrkrankenhaus Ulm Ulm
Germany Universitätsklinikum Ulm Ulm

Sponsors (7)

Lead Sponsor Collaborator
Universität des Saarlandes AstraZeneca, Saarland University Medical Center, University Hospital of Gießen and Marburg, University Hospital Regensburg, University of Leipzig, Wuerzburg University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) investigator assessed PFS, defined by the time between the day of randomization until one of the following events occurs, whichever comes first: Disease progression (PD), relapse after complete remission (CR) or death due to any cause, as per Lugano Classification of 2014. Patients who have not experienced an event at the time of analysis will be censored at the most recent date of disease assessment. Up to 5 years
Secondary Overall survival (OS) OS, defined by the time between the day of randomization until death due to any cause. Patients who have not experienced an event at the time of analysis will be censored at the date when the patient was last known to be alive. Up to 5 years
Secondary PFS based on blinded independent central review (BICR) Up to 5 years
Secondary Event-free survival (EFS) EFS, defined by the time between the day of randomization until one of the following events occurs, whichever comes first: Progressive disease (PD), relapse after complete remission (CR), initiation of subsequent systemic anti-lymphoma treatment and/or irradiation or death due to any cause, as per Lugano Classification of 2014. Up to 5 years
Secondary PFS according to Cell of Origin as per immunohistochemistry Up to 5 years
Secondary OS according to Cell of Origin as per immunohistochemistry Up to 5 years
Secondary EFS according to Cell of Origin as per immunohistochemistry Up to 5 years
Secondary PFS according to molecular genotype Up to 5 years
Secondary OS according to molecular genotype Up to 5 years
Secondary EFS according to molecular genotype Up to 5 years
Secondary Complete (CR) partial (PR) and overall (ORR) remission rates Up to 5 years
Secondary Duration of Response (DoR) Up to 5 years
Secondary Progression rate, relapse rate and central nervous system (CNS) relapse rate Up to 5 years
Secondary Adverse events (AEs), Serious AEs, AEs of special interest, events of clinical interest, AEs leading to study treatment discontinuation or dose modification. Up to 5 years
Secondary Rate of secondary malignancies Up to 5 years
Secondary Treatment-related death rate Up to 5 years
Secondary Dose intensity of miniCHOP, rituximab and acalabrutinib. Up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04670029 - Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line Phase 3
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Active, not recruiting NCT04572763 - Copanlisib Plus Venetoclax in R/R DLBCL Phase 1/Phase 2
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Completed NCT03287817 - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Phase 1/Phase 2
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed NCT04316624 - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy Phase 1
Active, not recruiting NCT04555811 - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Phase 1
Terminated NCT04189952 - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Phase 2
Recruiting NCT01949818 - Treatment of Diffuse Large B Cell Lymphoma Phase 4
Completed NCT01459887 - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Phase 3
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT05018520 - The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk Phase 3
Withdrawn NCT04052061 - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT05020392 - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma Phase 3
Recruiting NCT05006716 - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1